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Available online 8 March 2016Background: Rare gene variants are important sources of schizophrenia vulnerability that likely interact with
polygenic susceptibility loci. This study examined if novel or raremissense coding variants in any of four different
signaling genes in sporadic schizophrenia cases were associated with clinical phenotypes in an exceptionally
well-characterized sample.
Method: Structured interviews, cognition, symptoms and life course features were assessed in 48 ethnically-
diverse cases with psychosis who underwent targeted exome sequencing of PTPRG (Protein Tyrosine Phospha-
tase, Receptor Type G), SLC39A13 (Solute Carrier Family 39 (Zinc Transporter) Member 13), TGM5
(transglutaminase 5) and ARMS/KIDINS220 (Ankyrin repeat-rich membrane spanning protein or Kinase D-
Interacting Substrate of 220 kDa). Cases harboring rare missense coding polymorphisms or novel mutations in
one or more of these genes were compared to other cases not carrying any rare missense coding polymorphisms
or novel mutations in these genes and healthy controls.
Findings: Fifteen of 48 cases (31.25%) carried rare or novelmissense coding variants in one ormore of these genes.
The subgroups signiﬁcantly differed in important features, including speciﬁc working memory deﬁcits for PTPRG
(n = 5); severe negative symptoms, global cognitive deﬁcits and poor educational attainment, suggesting a
developmental disorder, for SLC39A13 (n = 4); slow processing speed, childhood attention deﬁcit disorder
andmilder symptoms for TGM5 (n=4); and global cognitive deﬁcits with good educational attainment suggest-
ing neurodegeneration for ARMS/KIDINS220 (n = 5). Case vignettes are included in the appendix.
Interpretation:Genes prone tomissense coding polymorphisms and/ormutations in sporadic casesmay highlight
inﬂuential genes for psychosis and illuminate heterogeneous pathways to schizophrenia. Ethnicity appears less
important at the level of genetic variability. The sequence variations that potentially alter the function of speciﬁc
genes or their signaling partnersmay contribute to particular subtypes of psychosis. This approachmay be appli-
cable to other complex disorders.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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ARMS/KIDINS2201. Introduction
It is likely that the genetic heterogeneity of the schizophrenia-
related psychoses will be pertinent to the development of optimal
person-speciﬁc treatments.We tested if a set of genes that had harbored
deleterious de novo mutations for schizophrenia in sporadic casesol of Medicine, Department of
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. This is an open access article undershowed other rare missense coding variants in an independent sample
that included familial and sporadic cases (Kranz et al., 2015a, 2015b).
Next we examined if cases harboring novel or rare variants in these
genes, independent of family history, differed in their clinical character-
istics. This report describes the phenotypes of subsets of cases with mis-
sense coding polymorphisms or novel mutations (“carriers”) in any of
four genes that act in different signaling pathways, which have been pre-
viously identiﬁed and replicated in independent cohorts: These are PTPRG
(Protein Tyrosine Phosphatase, Receptor Type G); SLC39A13 (Solute Car-
rier Family 39 (Zinc Transporter) Member 13); TGM5 (Transglutaminase
5); andARMS/KIDINS220 (AnkyrinRepeat-RichMembrane-SpanningPro-
tein or KinaseD-Interacting Substrate of 220 kDa). These genes are poten-
tially relevant for psychosis. In addition to the presence of rare missensethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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parison to healthy parents, each gene is highly expressed in the central
nervous system, involved in signaling pathways for neuronal network in-
tegration, stabilization, and connectivity. Almost a third of the cases in this
sample carried rare missense coding polymorphisms or novel mutations
in one or more of them (Kranz et al., 2015a, 2015b).
We hypothesized that these genetic variants, especially in known
protein interaction domains within each gene, might differentially
inﬂuence multilevel psychosis phenotypes. This report describes the
phenotypes of the respective gene carrier subgroups and provides clin-
ical vignettes on each case serving as a molecular-era case series with
implications for treatment. The information is based on rigorous clinical
research diagnostic and assessment procedures.
2. Materials and methods
2.1. Sample ascertainment and diagnosis
The study, a component of an NIMH Challenge Grant to examine
multilevel phenotypes and genomics in a sample of cases with chronic
psychosis, was approved by the Bellevue Hospital Center and NYUMed-
ical Center Institutional ReviewBoards and all subjects providedwritten
informed consent. Cases with chronic psychosis were recruited from
clinical treatment settings if they were taking stable medication doses
for at least one month. Healthy controls were recruited from Internet
postings and university announcements. Research assessments were
conducted by trained and reliable master's and doctoral level clinicians
using the Diagnostic Interview for Genetic Studies (DIGS) (Nurnberger
et al., 1994); Positive and Negative Syndrome Scale (PANSS), (Kay
et al., 1987) which were scored using positive, negative and general
psychopathology scales, the pentagonal ﬁve factor model (White et al.,
1997) and as the sum of the positive minus the negative scale scores
to indicate if the prominent symptom proﬁle was positive (Type 1) or
negative (Type 2) (Crow, 1997); Social Adjustment Scale (SAS)
(Weissman and Bothwell, 1976); Chapman Scales for Physical and So-
cial Anhedonia (Chapman et al., 1976); and Young Mania Rating Scale
(Young et al., 1978). Wechsler Adult Intelligence Scale, Third Edition
(WAIS-III) (Wechsler, 1997) results yielded Full Scale (FS), Verbal
(VIQ) and Performance IQ (PIQ) scores and indices of Verbal Compre-
hension (VCI), Perceptual Organization (POI), Working Memory
(WMI), and Processing Speed (PSI).
2.2. Targeted exome capture
Cases underwent targeted exome capture as described in detail in
previous studies (Kranz et al., 2015a, 2015b). Brieﬂy, all annotated
exons of the de novo JPSS genes were sequenced using the following
methodology. DNA (500 ng) from each sample was sheared to an
average of 150 bp in a Covaris instrument for 360 s (duty cycle—10%; in-
tensity—5; cycles/burst—200). Barcoded libraries were prepared using
the Kapa Low-Throughput Library Preparation Kit Standard (Kapa
Biosystems). Libraries were ampliﬁed using the KAPA HiFi Library
Ampliﬁcation kit (Kapa Biosystems) (8 cycles) and quantiﬁed using
Qubit Fluorimetric Quantitation (Invitrogen) and Agilent Bioanalyzer.
An equimolar pool of the four barcoded libraries (300 ng each) was
used as input to exon capture using one reaction tube of the custom
Nimblegen SeqCap EZ (Roche) with custom probes targeting the coding
exons of the genes of interest. Capture by hybridization was performed
according to the manufacturer's protocols with the following modiﬁca-
tions: 1 nmol of a pool of blocker oligonucleotides and (B) post-capture
PCR ampliﬁcation was done using the KAPA HiFi Library Ampliﬁcation
kit instead of the Phusion High-Fidelity PCRMaster Mixwith HF Buffer
Kit, in a 60 μl volume, since we found a greatly reduced or eliminated
the bias against GC-rich regions. The pooled capture library was quanti-
ﬁedbyQubit (Invitrogen) andBioanalyzer (Agilent) and sequencedon a
Illumina MiSeq or HiSeq 2500 sequencer using the 2 × 150 paired-endcycle protocol. The average coverage across all samples was 190×
(133 × −360×). Over 97% of the target region had coverage of over
50× in all samples. Reads were aligned to hg19 build of the human ge-
nome using BWAwith duplicate removal using samtools as implement-
ed by the IlluminaMiSeq Reporter. Variant detection and annotation
were performed with GATK Uniﬁed Genotyper Charity annotator and
cross-referenced against known dbSNP, 1000 Genomes, COSMIC muta-
tions and Schizophrenia Genebook entries. Only previously reported
rare missense coding variants (MAF b 0.01 in 1000g2012apr_all) and
unreported novel mutations were considered in this study and were
analyzed by Polyphen-2.
Brief clinical vignettes (see appendix) were prepared for cases with
missense coding polymorphisms (minor allele frequency b .01) or novel
mutations (“carriers”) (Kranz et al., 2015a, 2015b), categorized as fol-
lows: “1” for PTPRG carriers; “2” for SLC39A13; “3” for TGM5; and “4”
for ARMS/KIDINS220 carriers. Cases carrying two of these genes were
categorized in the above order for the ﬁrst gene, an asterisk (*) indicat-
ing that they carried others of these genes. The sequenced cases with
common variants in all of these genes were categorized as “non-car-
riers” for comparison, although they certainly have other genetic sus-
ceptibility. The carrier groups were statistically compared to groups of
non-carrier cases and healthy controls. Each gene carrier group was
then independently compared to the non-carrier case group by separate
ANCOVA analyses utilizing a Bonferroni corrected signiﬁcance level of
p b .01 in light of the multiple testing. The mean age differs due to the
different counts in particular analyses.
3. Results
Fifteen of the 48 cases (31.25%) carried missense coding ultra-rare
polymorphisms or novel mutations: 5 in PTPRG, 4 in SLC39A13, 4 in
TGM5, and 5 in ARMS/KIDINS220, as previously reported in Kranz et al.,
(2015a, 2015b). Three carried more than one rare missense coding
polymorphism in different genes considered in this analysis: one case
harbored PTPRG and SLC39A13 polymorphisms; another harbored rare
polymorphisms in both SLC39A13 and ARMS/KIDINS220; and the third
case had rare missense coding polymorphisms in ARMS/KIDINS220
and TGM5. The latter case had chronic psychosis but did not meet strict
DSM-IV schizophrenia or schizoaffective criteria based on confounding
by continuous substance abuse. One PTPRG and one ARMS/KIDINS220
variant carrier did not complete all assessments. As described in the vi-
gnettes (appendix) known risk factors for psychosis were common in
the carrier cases, including premorbid brain injury, substance abuse,
prematurity, and a family history of psychosis. Thyroid disorders were
common to all carrier groups, despite none having received lithium
pharmacotherapy. Comparing the four carrier groups to non-carrier
cases showed no differences in sex, age, or ethnicity.
As shown in Table 2, ARMS/KIDINS220 and SLC39A13 variant carriers
had lower mean verbal and full scale IQ scores and had more severe
general psychopathology symptoms than the other groups. The
SLC39A13 variant carriers also had more severe negative symptoms. In
addition the PTPRG and SLC39A13 variant carriers cases had an early
onset age shown in Table 1. Just one of the SLC39A13 carriers graduated
from high school (differing from the non-carriers), whereas all PTPRG
carriers with onset after age 17 years attained some college education
and employment. The SLC39A13 carriers notably had signiﬁcantly
more suicide attempts, whereas no PTPRG or TGM5 carriermade any sui-
cide attempt. Childhood learning disorders, based on the clinical inter-
view reports, were signiﬁcantly more commonly reported for PTPRG
carriers (100%) and signiﬁcantly less common for TGM5 carriers (0%).
Conversely, half of the TGM5 carriers had reported a history of attention
deﬁcit disorder, which signiﬁcantly differed from non-carriers. Depres-
sion and substance abuse rates were high in all cases groups. SLC39A13
variant carriers reported the greatest number of medical comorbidities
and both they and the ARMS/KIDINS220 variant carriers experienced
signiﬁcantly more degenerative joint disease.
Table 1
Descriptive measures by disrupted gene carrier groups.
PTPRG
(n = 5)
SLC39A13
(n = 4)
TGM5
(n = 4)
ARMS/KIDINS220
(n = 5)
Other cases
(n = 32)
Demographics
Sex: male 100% 50% 50% 60% 60.6%
Mean age 44.4 (7.1) 48.5 (6.4) 39.0 (14.5) 46.0 (11.3) 42.9 (8.9)
Mean age of onset 17.4 (7.9) Ϯ 18.0 (3.7) Ϯ 26.3 (9.5) 24.8 (8.9) 21.3 (6.8)
Ethnicity^ AA = 4, H = 1 AA = 3,
H = 1
AA = 1, ME = 1, H = 1,
C = 1
AA = 3, C = 2 AA = 17, H = 6,
C = 8, A = 1
Education:
b hs/hs/college
1/1/3 3/0/1 ϮϮ 0/2/2 1/1/2 2/10/21
Psychosis onset
b16 years
40% 50% 0% 0% 29%
Psychiatric comorbidities
Major depression 40% 75% 50% 40% 68%
Suicide attempt 0% Ϯ 75% Ϯ 0% 20% 48%
Substance abuse 100% 100% 100% 100% 68%
Medical Comorbidities:
Thyroid disorder 40% 25% 25% 20% b1%
Degenerative Joint disease 60% 100% Ϯ 25% 80% Ϯ 28%
Diabetes 20% 50% 25% 40% 19%
Migraines 40% 75% 75% 20% 22%
Birth complications 60% 0% 0% 0% 25%
Learning comorbidities:
Learning disabilities 100% Ϯ 75% 0% 40% 25%
Attention deﬁcit disorder 20% 25% 50 Ϯ 0% b1%
Each carrier group independently compared to non-carrier group by separate ANCOVA analyses for continuousmeasures or by Fisher's exact tests for categorical measures: Ϯ=p b .050,
ϮϮ= p b .01.
*Sex and ethnicity transposed for conﬁdentiality, actual ethnicity and sex numbers maintained.
**Table includes 3 dual hit cases and 2 cases with incomplete assessments.
***The sum of case numbers by missense genes are N15 since several cases had rare missense coding variants in more than one of these genes.
(%) Rounded to nearest whole number.
^Ethnicity: AA: African American, ME: Middle Easters, C: Caucasian, H: Hispanic, A: Asian.
#Education: bhs/hs/college: Less than high school/High school diploma or GED/At least some college.
+Incomplete data on 1 case; ++ incomplete data on 2 cases.
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controls (Table 2) showed group effects for all measures, except physical
anhedonia, and WAIS Perceptual Organization, Verbal Comprehension,
andWorkingMemory indexes. Examining symptoms among case groups
showed signiﬁcant effects for psychopathology (p b .008), with SLC39A13
carriers having the most severe symptoms and being signiﬁcantly more
symptomatic than TGM5 and non-carriers. SLC39A13 had the highest
mania and negative symptoms and it was noteworthy that it was the
only group to show a preponderance of negative versus positive symp-
toms, although not statistically signiﬁcant in these small samples. Scores
for social and physical anhedonia and social adjustment did not differ sig-
niﬁcantly across these groups.
Multiple separate ANCOVA analyses comparing eachmutation carrier
group to the non-carriers, adjusting for sex, age, and age of onset showed
SLC39A13 had higher scores for general psychopathology (F[1,27] =
10 ∙45, p = .003) and activation (F[1,27] = 8.79, p = .006) meeting the
studies Bonferroni corrected signiﬁcance level of b .01, with other consis-
tent but only marginally signiﬁcant results for autism (F[1,27] = 6.17,
p= .02), PANSS negative scale scores (F[1,27] = 5.28, p= .03) and neg-
ative factor scores (F[1,27]=5.52, p= .026). Findings formore social an-
hedonia (F[1,29] = 3.99, p = .055) and worse social function (F[1,29] =
3.94, p= .057) were also consistent with the negative symptoms but did
not reach study criteria for signiﬁcance. The ARMS/KIDINS220 carriers
demonstrated the highest autistic factor scores of any group (F[1,26] =
5.51, P = .027). By contrast, ratings for TGM5 carriers were similar in all
measures to the non-carrier group of cases and these two groups had
the lowest positive symptoms scores.
PANSS symptoms conﬁgured into factors are shown in Fig. 1. The
proﬁles are of interest although the differences did not achieve signiﬁ-
cance. The groups showed similar positive symptoms (F = 1.5 (4,35),
p = .22), with marginal group effects for negative (F = 2.2 (4,35),
p = .09), activation (F = 2.4 (4,35), p = .07), and dysphoric moodfactors (F = 2.3 (4,35), p = .08). The severe symptoms of the
SLC39A13 carriers drove these effects (higher negative symptoms than
TGM5, ARMS/KIDINS220, and non-carriers; higher activation scores
than TGM5; and higher dysphonic mood scores than TGM5 and non-
carrier cases). The trend-level group difference in the autistic factor
(F = 3.1 (4,35), p = .027) was driven by higher autistic scores for the
ARMS/KIDINS220 variant carriers.
Cognitive data is presented in Fig. 2a for IQ scores and 2b for theWAIS
indices. TheWAIS Processing Speed Index (PSI), ameasure of one's ability
to process simple visual information quickly and to efﬁciently perform
tasks based on that information, signiﬁcantly differed based on gene
groups (p b .008). Other comparisons, while not signiﬁcant, suggest di-
verse proﬁles of cognitive functioning. TGM5 carriers were the slowest
and this index was their weakest compared to all other indexes. ARMS/
KIDINS220 demonstrated the second slowest processing speed but they
scored similarly on all of the cognitive measures. PTPRG carriers had the
fastest PSI, but they (and SLC39A13 carriers) showed weakness on the
WorkingMemory index,which is ameasure of short-termmemory skills,
concentration, and the ability to mentally manipulate information. As PSI
was notably better than the otherWAIS indices for SLC39A13, impairment
in this domain is unlikely to have driven their pathology.
4. Discussion
Despite the relatively small numbers of cases with genetic alter-
ations in these particular signaling genes, this study demonstrated dif-
ferent multilevel phenotypes for groups of cases with schizophrenia-
related psychoses based on which of the sequenced genes harbored
rare missense coding polymorphisms or novel mutations in PTPRG,
SLC39A13, TGM5, and ARMS/KIDINS220. The allele frequencies of all
rare missense coding polymorphisms was b2% in accordance to the re-
spective ethnicity. Moreover, it is noteworthy that some of these rare
Table 2
Group measures and comparisons of mutation carriers, other cases and control groups.
PTPRG Carriers SLC39A13 Carriers TGM5 Carriers ARMS/KIDINS220
Carriers
Cases without mutations in
any of these four genes
Healthy Controls ANOVA with
all groups
ANOVA without
control group
F
(df)
P F
(df)
P
Age N = 5 N = 4 N = 4 N= 5 N= 32 N = 20 2.75 (5,58) .027 1.87 (4,39) .136
37.0(9.8) 47.7(7.5) 33.3(11.2) 49.0(3.6) 43.3(9.0) 36.8(8.7)
Positive Scale 4 3 3 3 27 19 10.87 (5,53) .001 1.66 (4,35) .181
16.3(4.9) 19.0(7.9) 13.7(2.9) 20.0(1.7) 14.2 (4.7) 7.6(1.8)
Negative Scale 4 3 3 3 27 19 10.14 (5,52) .001 2.36 (4,35) .072
15.5(2.6) 22.7(1.2) 13.3(6.7) 14.3(.58) 14.1(5.0) 8.2(1.5)
General Psychopath-Ology 4 3 3 3 27 19 16.93 (5,53) .001 4.07 (4,35) .008
33.5(5.4) 40.7(7.6) 25.3(3.1) 36.7(9.7) 28.1(6.4) 17.9(2.9)
Positive minus Negative Scale 4 3 3 3 27 19 1.07 (5,53) .385 0.86 (4,35) .498
.75(6.7) −3.7(7.6) .33(8.6) 5.7(1.2) .11(6.1) −.53(1.8)
Mania Scale 4 3 3 3 28 19 5.63 (5,54) .001 1.08 (4,36) .383
10.0(9.0) 14.7(11.9) 9.0(8.0) 11.0(5.6) 6.9(6.2) .68(1.9)
Physical Anhedonia 3 3 3 3 29 17 1.80 (5527) .129 0.59 (4,36) .672
21.0(8.2) 16.3(6.7) 17.3(15.0) 13.3(9.1) 15.7(5.1) 11.2(6.4)
Social Anhedonia 3 3 3 3 29 17 6.81 (5,52) .001 1.10 (4,36) .372
15.0(7.6) 22.3(10.3) 13.3(7.6) 18.7(6.4) 15.0(6.1) 6.8(3.6)
Social Adjustment 3 3 3 3 29 18 5.23 (5,53) .001 1.05 (4,36) .397
2.7(.78) 2.6(.28) 1.9(.16) 2.1(.99) 2.3(.56) 1.6(.32)
VIQ 4 3 3 3 27 18 3.39 (5,52) .010 0.62 (4,35) .651
89.8(17.0) 74.0(4.4) 88.3(22.0) 81.7(5.9) 88.5(17.3) 103.7 (13.1)
PIQ 4 3 3 3 27 18 3.57 (5,52) .008 0.71 (4,35) .593
92.3(20.7) 75.7(3.1) 81.7(21.7) 78.3(9.3) 84.5(14.4) 100.2 (14.3)
FSIQ 4 3 3 3 27 18 4.00 (5,52) .004 0.76 (4,35) .559
90.0(19.8) 72.7(1.5) 84.0(22.6) 77.7(1.2) 86.4(16.1) 102.4 (13.3)
VCI 4 3 3 3 27 18 2.93 (5,52) .021 0.82 (4,35) .520
95.3(18.7) 77.3(7.6) 92.7(24.2) 83.3(6.4) 93.0(17.2) 105.6 (11.9)
POI 4 3 3 3 27 18 2.25 (5,52) .063 0.59 (4,35) .674
95.0(18.8) 78.0(5.3) 87.3(19.0) 80.3(11.2) 86.1(16.6) 99.1(14.0)
WMI 4 3 3 3 27 18 3.16 (5,52) .015 0.90 (4,35) .474
81.5(19.6) 70.3(4.6) 85.0(20.9) 88.3(7.8) 86.9(14.9) 100.9 (17.3)
PSI 4 3 3 3 27 18 5.84 (5,52) .001 0.52 (4,35) .719
88.8(24.0) 83.3(10.0) 75.0(15.9) 80.0(11.5) 83.0(11.0) 103.0 (14.9)
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Fig. 1. PANSS pentagonalmodel factor scores. Signiﬁcant group differences are demonstrated on all measures, at p b .001, with respective F values for negative= 9.6 (5,53), positive= 9.5
(5,53), activation = 6.7 (5,53), dysphoric mood = 9.0 (5,53) and autistic = 8.2 (5,53) factors.
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group in the 1000 Genomes project (Table 3). These results suggest that
a meaningful proportion of the genetic complexity of the psychoses
may be resolved by focussing on the CNS signaling genes that had
been identiﬁed as harboring de novomissense coding variants in spo-
radic cases. Previous large-scale studies performing whole exome se-
quencing in schizophrenia cases (familial and non-related individuals)
showed that rare polymorphisms and mutations are enriched in genes
involved in synaptic plasticity and neuronal development (Purcell
et al., 2014; Fromer et al., 2014) and our analysis of the multilevel phe-
notypes for several such genes show this body of workmay be relevant
for the development of precision treatment. In concordance with other
large-scale analyses, these ﬁndings support the contention that schizo-
phrenia is not a single disease, but is a group of distinct disorders for
which major inﬂuential genes harboring rare disruptive variants may
be discerned (Arnedo et al., 2015) and for which speciﬁc treatments
may be developed.
As to the signiﬁcant differences, PTPRGmissense coding variant car-
riers had signiﬁcantly earlier onset of psychosis and each had a history
of learning disabilities. PTPRG is a protein tyrosine phosphatase highly
expressed in the hippocampus, striatum and neocortex and is highly
upregulated during neuroinﬂammatory processes (Lorenzetto et al.,
2014). Despite their earlier onset, those without childhood psychosis
attained some college education and employment. Their cognition was
intact,with the exception of impairedworkingmemory.Workingmem-
ory is a neurocognitive domain that is amajor target of treatment devel-
opment in schizophrenia (Schwarz et al., 2016). None of the PTPRG
variant carriers reported a suicide attempt despite their high rates of co-
morbid depression. While this is the ﬁrst comprehensive phenotypic
description for PTPRG missense coding variant carriers, a number of
genome-wide association studies (GWAS) (Hamshere et al., 2009;
Schizophrenia Psychiatric Genome-Wide Association Study C, 2011)
have supported the relevance of PTPRG as risk loci for bipolar disorder,
schizoaffective disorder, and major depression (Shi et al., 2011;
WellcomeTrust Case Control C, 2007). A recentwhole genome study ac-
complished in nine schizophrenia cases with the 22q11.2 deletion syn-
drome showed that PTPRG is enrichedwith deleteriousmissense coding
variants (Merico et al., 2015). The current work in combination with
previous genetic studies on neuropsychiatric cases supports the ideathat the phenotype of such casesmay add importantly to relevant geno-
types and phenotypes in schizophrenia.
Cases with rare missense coding variants in SLC39SA13, a zinc trans-
porter, also displayed an early onset but they showed globally disrupted
cognition and the most severe psychopathology, including negative
symptoms and severe suicide attempts. They had the lowest intelli-
gence and least educational attainment. Working memory was im-
paired comparably to other cognitive domains in these cases and since
processing speed was their strongest domain, it is also unlikely to be
driving their pathology. They had the greatest medical morbidity, in-
cluding degenerative joint diseases, consistent with the gene's role in
connective tissue development (Fukada et al., 2008). The psychiatric
ﬁndings are concordant with the SLC39A13 animal knockout model
(Hagmeyer et al., 2014), which shows analogous features to depression
including anxiety, aggression, and impaired social functioning. Interest-
ingly, these symptoms were alleviated with zinc supplements in ro-
dents and rhesus monkeys (Hagmeyer et al., 2014), suggesting a
possible treatment option. Furthermore, another study investigating a
constitutive knockout mouse model of SLC39A13 shows impairment of
the BMP/TGFβ signaling pathway (Fukada et al., 2008). A recent study
performed on the superior temporal gyrus in post-mortem schizophre-
nia (n = 9) and control brains (n = 9) yielded that mRNAs of the
BMP/TGFβ signaling pathway were differentially expressed (Pietersen
et al., 2014). Moreover, the severity of the zinc deﬁciency in the
SLC39A13 knockout mice appears to be associated with the severity of
depressive symptoms (Maes et al., 1994; Amani et al., 2010).
TGM5 cases had less severe symptoms than the other gene carrier
groups. TGM5 is highly expressed in the epidermis and mutations are
causative for acral peeling skin syndrome (Pigors et al., 2012; van der
Velden et al., 2012). In addition, TGM5 is expressed in fetal brain,
substantia nigra, temporal lobe and the spinal cord (Grenard et al.,
2001). We identiﬁed the rare missense coding polymorphisms in par-
ent–child trios diagnosed with schizophrenia (Kranz et al., 2015a) and
in an independent cohort of 48 schizophrenia cases presented in this
study. All but one case attended college and their onset of psychosis oc-
curred later in life. None reported suicide attempts or alcohol abuse and
only half were cigarette smokers. Notably, childhood attention deﬁcit
disorder affected each of these cases, perhaps owing to particularly
slow processing speed, which could also drive their pathophysiology.
Fig. 2. a. Boxplots of mean IQ scores by group. b. Boxplots of mean WAIS Indices scores by group.
211T.M. Kranz et al. / EBioMedicine 6 (2016) 206–214Given the fewer medical comorbidities and lower propensity for sub-
stance abuse, TGM5 may convey a less debilitating form of
schizophrenia.
ARMS/KIDINS220 carriers showed a picture consistent with low bor-
derline intelligence and diminishing education and employment over
earlier ages are inferred, since each completed at least one year of col-
lege (excluding dual-hit cases). While they showed the second slowest
processing speeds after the TGM5 carriers, all of their cognitive mea-
sureswere similarly impaired. Ankyrin repeat-richmembrane spanning
protein (ARMS) or KIDINS220 (Kinase D-Interacting Substrate of
220 kDa) is a scaffold protein, which is a substrate of protein kinase D
and neurotrophin receptors (Iglesias et al., 2000; Kong et al., 2001). In
addition, it is a major signaling hub protein in the neurotrophinpathway as well as in ephrin signaling (Neubrand et al., 2012). It is im-
portant in the nerve growth factor-induced signaling (Rogers and Schor,
2013) and reveals dysregulated expression patterns in and Alzheimer's
disease (Lopez-Menendez et al., 2013). In addition, mice with a consti-
tutive heterozygous mutation of ARMS/KIDINS220 display neuronal
loss in the frontal cortex and entorhinal cortex resulting in a deﬁcit in
spatial memory (Duffy et al., 2011).
It is worth noting that the analyses of illness features accompanying
particular affected genes were binary and not subjected to multiple
comparison considerations, as each case either harbored a particular
gene with missense coding polymorphisms or mutations or they did
not. Adjustments for multiple comparisons were considered in deﬁning
the differences between the gene-based subgroups.
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score proﬁle (Fig. 1) may be illuminating as to common and unique
pathologies. PTPRG carriers uniquely showed comparable high levels
of positive symptoms and dysphoric mood. ARMS/KIDINS220 carriers
showed similar high scores on most symptom factors, yielding the
highest autistic factor score, but a lower factor score for activation,
reﬂecting lesser hostility. SLC39A13 carriers showed the greatest
levels of all psychopathology and especially negative symptoms. Fi-
nally, TGM5 carriers and the group of cases without rare missense
coding genetic variants in any of these genes were almost indistin-
guishable in proﬁles and severity. Both groups showed roughly dou-
bled scores of the healthy controls in the same distribution. Given
their possibly slower processing speed of these TGM5 carriers, slow
processing speed may also be common in the cases that did not
carry missense coding variants in any of these particular genes and
may be an important target for treatment in these cases.
A recent study demonstrated three psychosis biotypes using a wide
biomarker panel, which clearly corroborates the need for further and
better alignment of endophenotypes with the underlying symptomato-
logical complexes (Clementz et al., 2015). Given the complementary
ﬁndings of our study, we propose that the biomarker panel can be an-
chored to rare gene variants in inﬂuential pathways. Only categorizing
the psychosis endophenotype as a categorical disorder may inadver-
tently minimize ﬁnding some important risk variants. It is also notable
that the respective potentially altered protein functions encoded by
these rare missense coding polymorphisms and novel mutations may
inﬂuence the clinical picture throughout the life course as the current
ﬁndings suggest. The birth complications, brain injuries, and premorbid
substance abuse common in the PTPRG carriers may reﬂect pleiotropic
effects of altered protein function, rather than a causal chain of expo-
sures. The ﬁndings also suggest that ethnicity may not be as large a
roadblock as had been expected for research in schizophrenia. The ini-
tial missense coding polymorphisms and mutations of these genes
were found in sporadic cases from Israeli and Afrikaner samples, yet dif-
ferent missense coding variants of each gene in the current study oc-
curred in African Americans and, for all but one gene, in a Hispanic
case. Ethnicity appears less important when gene function is consid-
ered, even if particular rare missense coding polymorphisms predomi-
nate in different ethnicities. It is of interest that at least half of the
cases in each carrier group had a ﬁrst-degree relative with psychosis.
Genes prone to harbor missense coding de novomutations, which typi-
cally occur in the male germ line and are transmitted to offspring in as-
sociation with paternal age in schizophrenia, may thus afterwards be
heritable to other generations and constitute important sources of
population-wide psychosis vulnerability.
These results do not prove causal relationships between these ge-
netic variations and phenotypes, but set the stage for replication and
mechanistic research to inform precision medicine. Despite the lim-
itation of this preliminary study (notably a small sample size), signif-
icant differences were found, even in conservative analyses,
supporting different phenotypic proﬁles for rare missense coding
variants in these genes. The authors are aware there can be limita-
tions in studying a small sample size. Numerous symptom indices
and cognitive measures were examined and described with mini-
mum attention to the many comparisons. However, the strength of
this study is the deep coverage of the target genes (N50× for 97% of
exon sequence (Kranz et al., 2015a, 2015b)), which enables high
conﬁdence of the detected variants and even the ability to ﬁnd ex-
tremely rare missense coding polymorphisms and mutations. In ad-
dition, we observed that these rare variants and novel mutations
are located in protein interaction domains and that one of the vari-
ants (ARMS/KIDINS220 H1085R) leads to reduced total protein ex-
pression (Kranz T.M., unpublished). Although some of the
Polyphen-2 predictions indicate that some of the polymorphisms
are benign, this is not likely to be the case in each instance. For exam-
ple biochemical analysis of some supposedly benign variants in a
213T.M. Kranz et al. / EBioMedicine 6 (2016) 206–214gene have actually revealed signiﬁcant effects on downstream sig-
naling in the encoded protein, as demonstrated for the Y1096 variant
in the rat ARMS/Kidins220, where the loss of tyrosine phosphoryla-
tion by mutation of this site leads to the loss of recruitment of the
adaptor protein CrkL and of sustained MAPK signaling (Arevalo
et al., 2004).
Although the inclusion of a control cohort would have been ideal for
internal validation of these sequence variation frequencies, our ﬁndings
of missense coding polymorphisms with allele frequencies of b1%, and
even novel mutations, suggests that these ﬁndings are sufﬁciently
supported to be of keen interest. A larger replication sample may
more reliably draw connections between gene variant and observed
phenotype and the stage will be set for a new approach to the disease
as being partly constituted by multiple independent subtypes of illness.
The difﬁculty in ﬁnding high impact genetic variation for psychoses
had lessened enthusiasm in the ﬁeld over whether particular genes or
phenotypes could be leveraged for person-speciﬁc interventions. Con-
versely, this report suggests that optimism may be appropriate for the
substantial portion of cases harboring abnormalities in genes prone to
de novomutations and rare missense coding polymorphisms in earlier
generations. As events in these genes were identiﬁed in more than
30% of the cases in this replication sample, these genes may inﬂuence
a substantial proportion of cases with chronic psychosis and become
targets for differential treatments. In particular, treatment approaches
may usefully address processing speed in TGM5 carriers, workingmem-
ory in PTPRG, zinc augmentation in SLC39A13, and neuroprotection in
ARMS/KIDINS220 carriers. Precision approaches can be informed by
knowledge of these genotypes to advance treatment for persons with
psychoses. Treatments found to lack efﬁciency in heterogeneous groups
of cases may be highly promising in selected groups of cases.5. Conclusions
These ﬁndings support the contention that single inﬂuential genes,
targeted for sequencing because they had harbored de novomutations
in sporadic cases compared to healthy parents in other studies, may
be inﬂuential with respect to the phenotypes of psychosis in unselected
cases and potentially relevant for treatment studies. Despite the rela-
tively small-sized subgroups based on the harboring of rare missense
polymorphisms in any of four different genes in this study, group dif-
ferences were demonstrated on multiple levels of the phenotype.
Knowledge about these genesmay be useful to identify relevant genetic
architectures for psychosis and in the development of person-speciﬁc
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